• 1. Excellent peroxidase mimicking property of CuO/Pt nanocomposites and their application as an ascorbic acid sensor?
  Xinhuan Wang,Shuangfei Cai,Cui Qi Analyst, 2017,142, 2500-2506
• 2. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 3. Enantiomorphic symmetry breaking in crystallization of molten sodium chlorate?
  Martin R. Ward,Gary W. Copeland,Andrew J. Alexander Chem. Commun., 2010,46, 7634-7636
• 4. Fate of Sb(v) and Sb(iii) species along a gradient of pH and oxygen concentration in the Carnoulès mine waters (Southern France)
  Eléonore Resongles,Corinne Casiot,Fran?oise Elbaz-Poulichet,Rémi Freydier,Odile Bruneel,Christine Piot,Sophie Delpoux,Aurélie Volant,Angélique Desoeuvre Environ. Sci.: Processes Impacts, 2013,15, 1536-1544
• 5. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Toluenes Tosyl compounds

Comprehensive Analysis of 5-(Ethylsulfamoyl)-2-methylbenzoic Acid (CAS No. 792953-99-2): Properties, Applications, and Industry Insights

5-(Ethylsulfamoyl)-2-methylbenzoic Acid (CAS No. 792953-99-2) is a specialized sulfonamide derivative with a growing presence in pharmaceutical and agrochemical research. This white to off-white crystalline powder, characterized by its molecular formula C10H13NO4S, has garnered attention for its unique structural features, including an ethylsulfamoyl moiety and a carboxylic acid functional group. The compound's molecular weight of 243.28 g/mol and balanced lipophilicity make it particularly valuable in drug discovery programs targeting enzyme modulation.

Recent studies highlight the compound's potential as a key intermediate in developing selective kinase inhibitors, aligning with current trends in precision medicine. Its benzoic acid core structure allows for versatile derivatization, addressing the pharmaceutical industry's demand for scaffold diversity. Analytical data from HPLC purity tests typically show ≥98% purity, with characteristic NMR peaks at 8.1 ppm (aromatic proton), 3.2 ppm (ethyl CH2), and 12.5 ppm (carboxylic acid proton). The compound demonstrates stability under ambient conditions but requires protection from prolonged light exposure, as indicated by accelerated stability studies.

The synthesis of 5-(Ethylsulfamoyl)-2-methylbenzoic Acid typically involves a multi-step protocol starting from 2-methyl-5-nitrobenzoic acid, proceeding through sulfonation and ethylamine conjugation reactions. Process chemists have optimized the route to achieve 70-75% overall yield while minimizing byproducts. This efficiency contributes to its cost-effectiveness in large-scale production – a critical factor for manufacturers addressing the growing demand for specialty chemicals in drug development pipelines.

In pharmaceutical applications, researchers are investigating this compound's role in designing next-generation anti-inflammatory agents, capitalizing on its ability to interact with COX-2 enzyme pockets. Computational modeling suggests favorable binding affinity scores (-8.2 kcal/mol in recent docking studies) for several therapeutic targets. The ethylsulfamoyl group appears crucial for selectivity enhancement, reducing off-target effects – a major focus area in current drug safety optimization strategies.

From a regulatory perspective, 5-(Ethylsulfamoyl)-2-methylbenzoic Acid complies with REACH registration requirements and shows favorable environmental fate parameters (Biodegradation Probability: 68% in OECD 301B tests). Its ecotoxicological profile (Daphnia magna EC50 >100 mg/L) supports sustainable use in industrial applications. These characteristics align with the pharmaceutical sector's increasing emphasis on green chemistry principles and environmental risk assessment during compound selection.

The global market for sulfonamide intermediates like 792953-99-2 is projected to grow at 6.2% CAGR through 2030, driven by expanding biologic drug conjugation applications and targeted therapy development. Supply chain analysts note particular demand from contract research organizations and generic drug manufacturers seeking to diversify their active pharmaceutical ingredient portfolios. Proper storage conditions (2-8°C in amber glass containers) and handling protocols (use of nitrile gloves and dust masks) ensure material integrity during transportation and use.

Analytical method development for 5-(Ethylsulfamoyl)-2-methylbenzoic Acid typically employs reverse-phase HPLC (C18 column, 0.1% formic acid/acetonitrile gradient) with UV detection at 254 nm. The compound's chromatographic behavior (retention time 6.8±0.2 minutes under standard conditions) facilitates quality control in production batches. Mass spectrometry confirms the molecular ion peak at m/z 244.1 [M+H]+, with characteristic fragment ions at m/z 200.0 (loss of CO2) and 154.9 (sulfonamide cleavage).

Emerging research explores the compound's utility in metal-organic framework synthesis and catalytic system design, leveraging its bidentate coordination capability. Materials scientists have reported successful incorporation into porous polymer networks for selective molecular recognition – an application gaining traction in environmental remediation technologies. These diverse applications underscore the importance of maintaining strict quality specifications (residual solvents <500 ppm, heavy metals <10 ppm) for research-grade material.

For researchers considering 5-(Ethylsulfamoyl)-2-methylbenzoic Acid in their work, proper solubility testing (soluble in DMSO >50 mg/mL, sparingly soluble in water) and pH stability profiling (stable at pH 4-8) are recommended during experimental design. The compound's logP value of 1.8 suggests good membrane permeability, though formulation scientists should evaluate salt formation options (sodium and potassium salts show improved aqueous solubility) for specific delivery requirements.

As the scientific community continues investigating structure-activity relationships in sulfonamide compounds, 792953-99-2 serves as a valuable reference point for medicinal chemistry optimization. Its balanced pharmacophore features and demonstrated synthetic accessibility position it as a versatile building block in both academic and industrial settings. Future developments may explore its potential in proteolysis targeting chimera (PROTAC) designs and other targeted protein degradation platforms currently revolutionizing drug discovery paradigms.

• 10252-64-9(4-(Ethylamino)sulfonylbenzoic Acid)
• 7326-74-1(3-(Ethylaminosulfonyl)benzoic acid)
• 62073-62-5(1,2-Benzenedicarboxylic acid, 4-[[(3-methoxypropyl)amino]sulfonyl]-)
• 886732-83-8(Benzoic acid, 3-[[[(3-methylphenyl)sulfonyl]amino]methyl]-)
• 7326-75-2(3-(N-Propylsulfamoyl)benzoic acid)
• 716358-46-2(3-(Isopropylamino)sulfonylbenzoic acid)
• 7326-77-4(3-Benzylsulfamoyl-benzoic acid)
• 90923-51-6(5-(Ethylsulfamoyl)benzene-1,3-dicarboxylic acid)
• 509094-11-5(Benzoic acid, 3-[[(2-fluoroethyl)amino]sulfonyl]-)
• 73713-64-1(copper(2+) bis[3-(ethylsulfamoyl)benzoate])